药物名称：YH003（CD40)

阶段：临床I期/II期

适应症：I期实体瘤；II期黑色素瘤，胰腺癌

开展地区：澳大利亚

试验名称： A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion  Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in combination with Toripalimab (anti-PD-1 mAb) in Subjects with Advanced Solid Tumors

试验链接：https://clinicaltrials.gov/ct2/show/NCT04481009